Last 47 quarters of trend data · Healthcare · Medical - Instruments & Supplies
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Utah Medical Products, Inc.'s quarterly P/E stands at 17.5x, down 2.1% year-over-year. EV/EBITDA has compressed 14.9% YoY to 7.3x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 19.26 | 17.49 | 19.20 | 15.14 | 15.23 | 17.87 | 16.40 | 17.04 | 16.31 | 17.84 | 19.91 | 20.26 | 20.42 |
| — | -2.1% | +17.1% | -11.2% | -6.6% | +0.1% | -17.6% | -15.9% | -20.1% | -11.3% | +10.1% | +5.7% | -12.7% | |
| P/S Ratio | 5.58 | 4.95 | 5.15 | 4.64 | 4.78 | 5.69 | 5.81 | 5.67 | 5.67 | 6.20 | 6.26 | 6.59 | 6.88 |
| — | -13.0% | -11.5% | -18.2% | -15.8% | -8.2% | -7.1% | -13.9% | -17.6% | -7.9% | +4.6% | +12.9% | +3.0% | |
| P/B Ratio | 1.82 | 1.50 | 1.71 | 1.57 | 1.58 | 1.77 | 1.87 | 1.90 | 2.01 | 2.38 | 2.53 | 2.79 | 2.92 |
| — | -15.4% | -8.9% | -17.4% | -21.3% | -25.5% | -25.9% | -31.7% | -31.0% | -25.5% | -11.7% | -4.5% | -3.2% | |
| P/FCF | 15.00 | 13.28 | 13.11 | 16.37 | 10.83 | 17.78 | 14.57 | 22.29 | 12.24 | 14.58 | 15.85 | 18.46 | 12.54 |
| — | -25.3% | -10.0% | -26.6% | -11.5% | +22.0% | -8.1% | +20.7% | -2.3% | -10.0% | +7.8% | +8.6% | -26.8% | |
| EV / EBITDA | 9.00 | 7.33 | 8.76 | 6.52 | 6.61 | 8.61 | 8.85 | 8.90 | 8.97 | 10.72 | 13.62 | 13.69 | 10.64 |
| — | -14.9% | -1.0% | -26.7% | -26.3% | -19.7% | -35.0% | -35.0% | -15.7% | +0.4% | +55.8% | +51.1% | +2.1% | |
| EV / EBIT | 11.34 | 7.52 | 8.91 | 6.70 | 7.39 | 9.61 | 8.65 | 8.73 | 8.85 | 11.57 | 16.40 | 16.42 | 13.61 |
| — | -21.7% | +3.0% | -23.2% | -16.5% | -16.9% | -47.3% | -46.9% | -35.0% | -8.6% | +40.0% | +34.1% | -6.7% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Utah Medical Products, Inc.'s operating margin was 27.0% in Q4 2025, up 0.4 pp QoQ and down 5.0 pp YoY. The trailing four-quarter average of 29.5% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 10.0% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 51.6% | 52.3% | 51.6% | 50.8% | 57.0% | 58.1% | 52.7% | 55.2% | 59.7% | 57.6% | 45.9% | 47.6% | 62.6% |
| — | -10.0% | -2.2% | -8.0% | -4.4% | +1.0% | +14.9% | +15.9% | -4.8% | -6.2% | -27.3% | -21.5% | +2.5% | |
| Operating Margin | 29.6% | 27.0% | 26.6% | 32.1% | 32.5% | 32.0% | 33.4% | 33.1% | 34.2% | 32.0% | 31.7% | 34.4% | 35.5% |
| — | -15.6% | -20.4% | -2.9% | -5.2% | +0.0% | +5.3% | -3.9% | -3.4% | -14.4% | -20.0% | -8.7% | -3.4% | |
| Net Margin | 29.3% | 28.4% | 26.8% | 30.6% | 31.3% | 31.7% | 35.6% | 33.2% | 34.9% | 34.8% | 31.5% | 32.6% | 33.7% |
| — | -10.5% | -24.7% | -7.8% | -10.2% | -8.8% | +13.2% | +1.7% | +3.6% | +3.6% | -4.8% | +6.8% | +17.4% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 9.5% | 2.2% | 2.2% | 2.6% | 2.6% | 2.4% | 2.9% | 2.7% | 3.1% | 3.4% | 3.2% | 3.5% | 3.6% |
| — | -10.1% | -22.3% | -5.3% | -16.1% | -29.4% | -10.5% | -21.7% | -14.8% | -16.9% | -19.2% | -7.5% | +11.0% | |
| ROA | 9.2% | 2.1% | 2.2% | 2.5% | 2.5% | 2.3% | 2.7% | 2.6% | 2.9% | 3.2% | 3.0% | 3.3% | 3.3% |
| — | -8.8% | -21.0% | -3.7% | -15.0% | -28.4% | -8.8% | -20.0% | -12.8% | -14.5% | -17.6% | -6.5% | +11.6% | |
| ROIC | 25.0% | 5.4% | 5.6% | 6.9% | 6.9% | 6.2% | 7.0% | 7.4% | 8.3% | 3.7% | 2.4% | 4.2% | 8.6% |
| — | -13.2% | -20.4% | -7.4% | -17.3% | +68.0% | +192.0% | +79.1% | -3.8% | -61.8% | -74.8% | -53.3% | +15.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Utah Medical Products, Inc.'s Debt/EBITDA ratio is 0.1x — comfortably within a safe range. The current ratio has improved 46.7% YoY to 37.62x, strengthening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | -21.4% | -15.3% | -1.8% | +3.0% | +4.4% | -2.4% | -14.3% | -19.7% | -23.0% | -24.6% | -24.4% | -20.6% | |
| Debt / EBITDA | 0.02 | 0.07 | 0.07 | 0.06 | 0.07 | 0.08 | 0.07 | 0.07 | 0.06 | 0.06 | 0.05 | 0.05 | 0.05 |
| — | -8.7% | -2.2% | -2.4% | +11.2% | +30.3% | +38.2% | +31.1% | +18.0% | +18.5% | +3.1% | -5.7% | -12.4% | |
| Current Ratio | 37.62 | 37.62 | 32.06 | 41.87 | 22.29 | 25.64 | 29.59 | 25.98 | 19.57 | 22.56 | 24.38 | 19.21 | 15.66 |
| — | +46.7% | +8.3% | +61.2% | +13.9% | +13.6% | +21.4% | +35.2% | +25.0% | +49.5% | +81.4% | +8.0% | +20.1% | |
| Quick Ratio | 34.57 | 34.57 | 29.36 | 38.22 | 20.29 | 23.29 | 26.94 | 23.68 | 17.89 | 20.53 | 22.06 | 17.24 | 14.02 |
| — | +48.4% | +9.0% | +61.4% | +13.5% | +13.5% | +22.1% | +37.3% | +27.6% | +50.9% | +82.1% | +6.9% | +18.6% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying UTMD stock.
Utah Medical Products, Inc.'s current P/E is 19.3x. The average P/E over the last 4 quarters is 16.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Utah Medical Products, Inc.'s current operating margin is 29.6%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Utah Medical Products, Inc.'s business trajectory between earnings reports.